Picture EBD Group BIO-Europe 2021 Time to Register 650x100
Document › Details

GlaxoSmithKline plc. (5/21/20). "Press Release: GSK Partners with Samsung Biologics to Secure Additional Manufacturing Capacity for Innovative Biopharmaceutical Portfolio". London & Songdo.

Organisations Organisation GlaxoSmithKline plc (LSE: GSK, NYSE: GSK)
  Group GlaxoSmithKline (GSK) (Group)
  Organisation 2 Samsung BioLogics Co., Ltd.
Products Product contract manufacturing (biologicals)
  Product 2 Benlysta®
Index term Index term GSK–Samsung: biologicals contract manufacturing, 202005–2028 supply up to $231m of Benlysta + other biologics by Samsung Biologics
Persons Person Simard, Regis (GSK 202005 President Pharmaceuticals Supply Chain)
  Person 2 Kim, Tae-Han (Samsung 201205– CEO of Samsung BioLogics)

For media and investors only

GlaxoSmithKline and Samsung Biologics have entered into a partnership to provide GSK with additional capacity to manufacture and supply GSK’s innovative biopharmaceutical therapies.

Under the terms of the agreement, Samsung Biologics will provide GSK with additional capacity for large-scale biopharmaceutical product manufacturing. This capacity will be flexible depending on GSK’s future needs and will supplement GSK’s existing manufacturing network.

Regis Simard, President, Pharmaceuticals Supply Chain, GSK, said, “Today’s agreement with Samsung Biologics complements and reinforces our existing world-class pharmaceutical manufacturing capability and will help ensure we can continue to deliver the transformative medicines that patients need.”

“We are very proud and excited to announce this long-term agreement with GSK,” said Dr. Tae Han Kim, CEO of Samsung Biologics. “Samsung Biologics entered the biopharma industry with the goal to help our clients bring valuable biological medicines to patients faster. We are thrilled to partner with GSK, a company who shares the vision.”

The agreement is worth more than $231 million US over the next eight years. It will initially cover commercial production of Benlysta (belimumab), with technology transfer starting in 2020 and first commercial supply expected in 2022. The intention is to expand to additional specialty-care products in the future.

About Samsung Biologics Co. Ltd.

Samsung Biologics is a fully integrated CDMO offering state-of-the-art contract development, manufacturing, and analytical testing services. With a proven regulatory approvals record, the largest capacity, and the fastest throughput, Samsung Biologics is an award-winning partner of choice and is uniquely able to support the development and manufacturing of biologics products at every stage of the process while meeting the evolving needs of biopharmaceutical companies worldwide. For more information, visit

About GlaxoSmithKline

GSK is a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer.

For further information, please visit

Press Contact:

Samsung Biologics | Claire Kim:
GSK | Tim Foley:

Record changed: 2020-05-28


Picture [iito] Made Without Love 650x80px

More documents for GlaxoSmithKline (GSK) (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture Berlin Partner Network in German Capital Region 650x80px

» top